6 recruiting, 3 active not recruiting, 3 completed, 2 withdrawn. 14 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 6, Active not recruiting 3, Completed 3, Withdrawn 2 |
| Phase 2 | 6 | Recruiting 4, Completed 1, Withdrawn 1 |
Follow Mosunetuzumab: new trials by email Literature Review of Mosunetuzumab trials Research Report on Mosunetuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mosunetuzumab for CLL MRD Clearance Mosunetuzumab, Ibrutinib, Acalabrutinib - Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Inhye Ahn | 40 | 2025-11-24 | 2025-12-15 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-10-26 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas BMS-986458, Rituximab, Glofitamab/Obinutuzumab - Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 460 | 2023-12-29 | 2026-10-23 |
| A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Mosunetuzumab - Refractory B-cell Acute Lymphoblastic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-07-05 | 2023-10-10 | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Mosunetuzumab, DHAX, ICE - Large B-cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 24 | 2023-01-03 | 2026-01-08 |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2022-12-22 | 2026-10-13 |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab - B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | ADC Therapeutics S.A. | 154 | 2022-06-17 | 2026-07-17 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Mosunetuzumab, Tocilizumab, Venetoclax - Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 1 | Recruiting | Hoffmann-La Roche | 332 | 2022-03-07 | 2026-11-05 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus Mosunetuzumab, Tocilizumab - Systemic Lupus Erythematosus | Phase 1 | Completed | Hoffmann-La Roche | 15 | 2022-01-11 | 2025-04-29 |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Tazemetostat, Tafasitamab, Lenalidomide - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Withdrawn | Epizyme, Inc. | 2021-12-22 | 2023-08-15 | |
| A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma Glofitamab, Gemcitabine, Oxaliplatin - B-cell Lymphoma | Phase 1 | Completed | Hoffmann-La Roche | 23 | 2020-06-04 | 2024-03-25 |
| A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Polatuzumab Vedotin, Rituxumab - B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 117 | 2019-03-08 | 2024-12-18 |
Lymphoma, B-Cell (5) · Lymphoma, Large B-Cell, Diffuse (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lupus Erythematosus, Systemic (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1)
Hoffmann-La Roche (4) · Washington University School of Medicine (2) · ADC Therapeutics S.A. (1) · BeOne Medicines (1) · Bristol-Myers Squibb (1) · Epizyme, Inc. (1) · Inhye Ahn (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (13) · Italy (4) · Poland (4) · Spain (4) · Australia (3) · China (3) · France (3) · Germany (3) · South Korea (3) · United Kingdom (3) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1)
Armin Ghobadi, M.D. (1) · David Russler-Germain, M.D., Ph.D. (1) · Inhye Ahn, MD (1) · Joseph M Tuscano (1) · Nitin Jain, MBBS (1) · Stephen E Spurgeon (1)
PMID 37581593, PMID 39908481, PMID 41670385, PMID 42309556
2018 (1), 2023 (1), UM1CA186717 (1)